Evidence Synthesis
Religare Pharmaceuticals reported a significant acceleration in its gross margin to 82.97% in the latest quarter, up from a loss of -2.62%.
Loading stock analysis…
Loading stock analysis…
Evidence Synthesis
Last synthesized: 17 Sept 2026, 04:27
See how this stock's evidence score moved across recent sessions — unlock Pro for the live chart.
Full momentum history unlocks with Pro or Research.
Evidence Synthesis
Religare Pharmaceuticals reported a significant acceleration in its gross margin to 82.97% in the latest quarter, up from a loss of -2.62%.
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 82.97 % | -2.62 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | -2.62 % | 0.55 | ▼ |
| REVENUE_GROWTH_YOY | 26 % | — | - |
| PRICE_CHANGE_PERCENT | 0.04 % | — | - |
| DAILY_VOLUME | 4,43,254 shares | 11,93,023 | ▼ |
| CLOSE_PRICE | 247.65 INR | 247.55 | ▲ |